Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Surgical Management
100%
Lymphadenectomy
100%
Cytoreductive Nephrectomy
100%
Advanced Renal Cell Carcinoma (aRCC)
100%
Targeted Therapy
83%
Locally Advanced
33%
Nephrectomy
33%
Metastatic Renal Cell Carcinoma (mRCC)
33%
Low-risk Patients
16%
Clinical Practice Guidelines
16%
Potential Therapeutics
16%
Randomized Clinical Trial
16%
Therapeutic Implications
16%
Well-defined
16%
Distant Metastasis
16%
Disease Pattern
16%
Patient Characteristics
16%
Biomarker Discovery
16%
Kidney Cancer
16%
Favorable Risk
16%
Survival Benefit
16%
Therapeutic Role
16%
Intermediate Risk
16%
Lymph
16%
Systemic Therapy
16%
Management Options
16%
Sunitinib
16%
High-risk Disease
16%
Best Management Practices
16%
Retrospective Data
16%
Evidence-based Management
16%
Risk Subset
16%
Sunitinib Malate
16%
Immediate Surgery
16%
Advanced Setting
16%
Liquid Biopsy
16%
CARMENA
16%
SURTIME
16%
Metastatic Kidney Cancer
16%
Medicine and Dentistry
Kidney Cancer
100%
Retroperitoneal Lymph Node Dissection
100%
Nephrectomy
100%
Surgery
100%
Targeted Therapy
71%
Diseases
42%
Immunotherapy
28%
Kidney Metastasis
28%
Sunitinib
28%
Biological Marker
14%
Morbidity
14%
Systemic Therapy
14%
Clinical Guideline
14%
Patient History of Nephrectomy
14%
Liquid Biopsy
14%
Metastatic Kidney Cancer
14%
Randomized Clinical Trials
14%